Tweets
J&J announced positive topline results from Phase 2b JASMINE study showing the efficacy of of nipocalimab, FcRn blocker that reduces AutoAbs & B cell activity. Study met its 24 wk primary endpoint (SRI-4 response) vs placebo. There were no new safety signals https://t.co/KMseKyGirt
Dr. John Cush @RheumNow ( View Tweet )
57 minutes 16 seconds ago
Kick off 2026 with #RheumNowLive—two days of cutting-edge rheumatology, rapid-fire STEP talks, interactive Q&A, and real-world insights with Drs. Jack Cush, Arthur Kavanaugh, and a powerhouse faculty.
Register: https://t.co/MVgXnacU5q https://t.co/7ajH7Ry0Uj
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 hours 57 minutes ago
“The practice of medicine is an art, not a trade; a calling, not a business; a calling in which your heart will be exercised equally with your head. – Sir William Osler
Dr. John Cush @RheumNow ( View Tweet )
5 hours 19 minutes ago
Anti-mitochondrial M2 Ab (AMA-M2) in 987 IIM pts-- 55 (6%) were AMA-M2 positive. AMA-M2+ had signif. higher rates of polymyositis (56% vs 23.5%), GGT, alk phos levels, & 3 fold more cardiac involvement (60 vs 13%) (arrhythmias, CHF, pulm HTN (31-56%), but no effect on survival https://t.co/8fQzgRfHr4
Dr. John Cush @RheumNow ( View Tweet )
8 hours 57 minutes ago
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis
The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/8VNQtP3Izj
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
UK study of 1846 RA pts starting a b/tsDMARDs, ~30% on steroids & majority (2/3) continued use over the first year of new novel treatment. This suggests these aer either severe RA pts or that we are not vigilant in limiting/weaning/stopping steroids in RA patients - which is it? https://t.co/TrAktincKT
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Japan retrospective study of 38 RA pts who developed MTX assoc lymphoproliferative disorder (LPD) - 22 w/ spontaneous regression (SR) vs 16 non-SR (w/ 5 deaths). non-SR Pt had higher LDH levels at Dx & lower lymphocyte recovery 1 mo. post MTX withdrawal & higher mortality risk https://t.co/TRizVwP2BQ
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Subcutaneous Anifrolumab Effective in Lupus
A new study published in Arthritis & Rheumatology demonstrates that subcutaneous administration of anifrolumab provides efficacy comparable to intravenous administration, offering a promising alternative for at-home care of patients https://t.co/KgBC8vJHuB
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
2025 Rheumatologists, In Memorium
In 2025, rheumatology lost many of its most influential clinicians, mentors, and colleagues. This honor roll recognizes those who cared for countless patients, shaped generations of rheumatologists, and left a lasting legacy in our field. As Dr.
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
DERM on RheumNow Podcast (December 2025)
https://t.co/icOauEOhLP https://t.co/eMt40WFiFD
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Shortened Leukocyte telomere length (PBL-TL) is assoc w/ systemic sclerosis–ILD. Study of PBL-TL in 244 SSc vs 314 controls, found signif shorter PBL-TL in SSC. Short PBL-TL was assoc w/ ILD & Pulm HTN, more lung related hospitalizations, but not w/ Raynauds, skin or vascular dz
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Plenty of evidence that toxic environmental exposures increase #RA risk. Full read, intelligent report from Stanhope et al showing how (healthy environmental) green space exposures are protective & capable of preventing RA!! Lifestyle is gigantically important in your https://t.co/LUWmHhUT7F
Dr. John Cush @RheumNow ( View Tweet )
2 days 3 hours ago
